drugset
drugset / Trial / NCT04593121

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants

NCT04593121 ↗

Phase 1 Completed 84 enrolled Biogen
RandomizedSequentialTriple-blindTreatment

Summary

The primary objective is to determine the safety and tolerability of single and multiple ascending subcutaneous (SC) doses and a single intravenous (IV) dose of BIIB107 in healthy adult participants. The secondary objectives are to characterize the single-dose pharmacokinetic (PK) of SC and IV BIIB107 in healthy adult participants and to characterize the multiple-dose PK of SC BIIB107 in healthy adult participants.

Timeline

Start
2020-10-30
Primary completion
2024-03-05
Completion
2024-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIB107 Monoclonal antibody — Subcutaneous

Indications

No indication recorded.